Enveric Biosciences Inc.

1.34
-0.05 (-3.60%)
Apr 01, 2025, 11:41 AM - Market open

Company Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care.

Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy.

Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Enveric Biosciences Inc.
Enveric Biosciences Inc. logo
Country United States
IPO Date May 4, 2015
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Dr. Joseph Edward Tucker Ph.D.

Contact Details

Address:
4851 Tamiami Trail North
Naples, Florida
United States
Website https://www.enveric.com

Stock Details

Ticker Symbol ENVB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000890821
CUSIP Number 29405E208
ISIN Number US29405E2081
Employer ID 95-4484725
SIC Code 2834

Key Executives

Name Position
Dr. Joseph Edward Tucker Ph.D. Chief Executive Officer & Director
Kevin M. Coveney CPA Chief Financial Officer
Dr. Peter J. Facchini Ph.D. Chief Innovation Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 8-K Current Report
Mar 28, 2025 10-K Annual Report
Mar 24, 2025 S-8 Filing
Mar 06, 2025 8-K Current Report
Feb 26, 2025 8-K Current Report
Feb 05, 2025 SCHEDULE 13G Filing
Feb 04, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 04, 2025 SCHEDULE 13G Filing
Feb 03, 2025 8-K Current Report
Feb 03, 2025 424B4 Filing